These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8718587)

  • 1. Complexed HIV envelope as a target for an AIDS vaccine.
    Gershoni JM; Denisova GF; Raviv D; Stern B; Zwickel J
    Adv Exp Med Biol; 1996; 397():91-6. PubMed ID: 8718587
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive response. Encouraging results in the search for an AIDS vaccine.
    Beardsley T
    Sci Am; 1991 Aug; 265(2):26. PubMed ID: 1862329
    [No Abstract]   [Full Text] [Related]  

  • 3. Human trials of AIDS vaccines: current status and future directions.
    Koff WC; Fauci AS
    AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
    [No Abstract]   [Full Text] [Related]  

  • 4. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 6. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
    Gao F; Weaver EA; Lu Z; Li Y; Liao HX; Ma B; Alam SM; Scearce RM; Sutherland LL; Yu JS; Decker JM; Shaw GM; Montefiori DC; Korber BT; Hahn BH; Haynes BF
    J Virol; 2005 Jan; 79(2):1154-63. PubMed ID: 15613343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodiversity and bioseparation of HIV-1 envelope glycoproteins.
    Shao Y; Lu Y
    Crit Rev Oncog; 1999; 10(1-2):1-16. PubMed ID: 10327209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

  • 9. Does the HIV envelope induce a chronic graft-versus-host-like disease?
    Habeshaw J; Hounsell E; Dalgleish A
    Immunol Today; 1992 Jun; 13(6):207-10. PubMed ID: 1627248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
    Sailaja G; Husain S; Nayak BP; Jabbar AM
    J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.
    Fouts TR; DeVico AL; Onyabe DY; Shata MT; Bagley KC; Lewis GK; Hone DM
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):129-34. PubMed ID: 12832116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.
    Zhan X; Slobod KS; Surman S; Brown SA; Lockey TD; Coleclough C; Doherty PC; Hurwitz JL
    J Virol; 2003 Apr; 77(7):4231-6. PubMed ID: 12634380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
    Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
    J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
    J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
    Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.